The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8

Adaptive Immunity Adjuvants, Immunologic / pharmacology CD8-Positive T-Lymphocytes / cytology Cells, Cultured Flow Cytometry Humans Inflammation Leukocytes, Mononuclear / cytology Ligands Lymphocyte Activation Oligodeoxyribonucleotides / pharmacology Peptides / chemistry RNA / metabolism Receptors, Pattern Recognition Toll-Like Receptor 9 / metabolism

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 07 2020
Historique:
received: 18 02 2020
accepted: 05 06 2020
entrez: 17 7 2020
pubmed: 17 7 2020
medline: 23 1 2021
Statut: epublish

Résumé

Toll-like receptor 9 (TLR9) agonists have gained traction in recent years as potential adjuvants for the induction of adaptive immune responses. It has nonetheless remained unclear to what extent such ligands can facilitate the priming events that generate antigen-specific effector and/or memory CD8

Identifiants

DOI: 10.1038/s41598-020-67704-0 PMID: 32669577 PMC: PMC7363897
pubmed: 32669577
doi: 10.1038/s41598-020-67704-0
pii: 10.1038/s41598-020-67704-0
pmc: PMC7363897
doi:

Substances chimiques

Adjuvants, Immunologic 0
CpG ODN 2006 0
Ligands 0
Oligodeoxyribonucleotides 0
Peptides 0
Receptors, Pattern Recognition 0
TLR9 protein, human 0
Toll-Like Receptor 9 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11620

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100326/Z/12/Z
Pays : United Kingdom

Références

Li, L., Goedegebuure, S. P. & Gillanders, W. E. Preclinical and clinical development of neoantigen vaccines. Ann. Oncol. 28, xii11–xii17. https://doi.org/10.1093/annonc/mdx681 (2017).
doi: 10.1093/annonc/mdx681 pubmed: 29253113 pmcid: 5834106
Nicoli, F. & Appay, V. Immunological considerations regarding parental concerns on pediatric immunizations. Vaccine 35, 3012–3019. https://doi.org/10.1016/j.vaccine.2017.04.030 (2017).
doi: 10.1016/j.vaccine.2017.04.030 pubmed: 28465096
Mutwiri, G., van Drunen Littel-van den Hurk, S. & Babiuk, L. A. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv. Drug Deliv. Rev. 61, 226–232. https://doi.org/10.1016/j.addr.2008.12.004 (2009).
doi: 10.1016/j.addr.2008.12.004 pubmed: 19162103
Gutjahr, A., Tiraby, G., Perouzel, E., Verrier, B. & Paul, S. Triggering intracellular receptors for vaccine adjuvantation. Trends Immunol. 37, 573–587. https://doi.org/10.1016/j.it.2016.07.001 (2016).
doi: 10.1016/j.it.2016.07.001 pubmed: 27474233
Speiser, D. E. et al. Rapid and strong human CD8
doi: 10.1172/JCI23373 pubmed: 15696196 pmcid: 546459
Appay, V. et al. New generation vaccine induces effective melanoma-specific CD8
doi: 10.4049/jimmunol.177.3.1670 pubmed: 16849476
Heikenwalder, M. et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10, 187–192. https://doi.org/10.1038/nm987 (2004).
doi: 10.1038/nm987 pubmed: 14745443
Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417–428. https://doi.org/10.1016/j.immuni.2006.07.013 (2006).
doi: 10.1016/j.immuni.2006.07.013 pubmed: 16973389
Allacher, P. et al. Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9. Blood 117, 259–267. https://doi.org/10.1182/blood-2010-06-289009 (2011).
doi: 10.1182/blood-2010-06-289009 pubmed: 20889922
Lee, J., Martinez, N., West, K. & Kornfeld, H. Differential adjuvant activities of TLR7 and TLR9 agonists inversely correlate with nitric oxide and PGE2 production. PLoS ONE 10, e0123165. https://doi.org/10.1371/journal.pone.0123165 (2015).
doi: 10.1371/journal.pone.0123165 pubmed: 25875128 pmcid: 4395302
Volpi, C. et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat. Commun. 4, 1852. https://doi.org/10.1038/ncomms2874 (2013).
doi: 10.1038/ncomms2874 pubmed: 23673637
Lissina, A. et al. Priming of qualitatively superior human effector CD8
doi: 10.4049/jimmunol.1501140 pubmed: 26608912
Gutjahr, A. et al. The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8
doi: 10.1172/jci.insight.125107 pubmed: 30944257
Li, J., He, Y., Hao, J., Ni, L. & Dong, C. High levels of Eomes promote exhaustion of anti-tumor CD8
doi: 10.3389/fimmu.2018.02981 pubmed: 30619337 pmcid: 6305494
Jia, B. et al. Eomes
doi: 10.1158/0008-5472.CAN-18-3107 pubmed: 30709927
Nambu, A., Nakae, S. & Iwakura, Y. IL-1β, but not IL-1α, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses. Int. Immunol. 18, 701–712. https://doi.org/10.1093/intimm/dxl007 (2006).
doi: 10.1093/intimm/dxl007 pubmed: 16569679
Temizoz, B. et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur. J. Immunol. 45, 1159–1169. https://doi.org/10.1002/eji.201445132 (2015).
doi: 10.1002/eji.201445132 pubmed: 25529558 pmcid: 4671267
Duramad, O. et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102, 4487–4492. https://doi.org/10.1182/blood-2003-07-2465 (2003).
doi: 10.1182/blood-2003-07-2465 pubmed: 12946990
Wingender, G. et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12–20. https://doi.org/10.1002/eji.200535602 (2006).
doi: 10.1002/eji.200535602 pubmed: 16323249
Nicoli, F., Paul, S. & Appay, V. Harnessing the induction of CD8
doi: 10.3389/fimmu.2018.02372 pubmed: 30410483 pmcid: 6209652
Mellor, A. L. et al. Cutting edge: CpG oligonucleotides induce splenic CD19
doi: 10.4049/jimmunol.175.9.5601 pubmed: 16237046
Krug, A. et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31, 2154–2163. https://doi.org/10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154gt;3.0.CO;2-U (2001).
doi: 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154gt;3.0.CO;2-U pubmed: 11449369
Welsh, R. M., Bahl, K., Marshall, H. D. & Urban, S. L. Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog. 8, e1002352. https://doi.org/10.1371/journal.ppat.1002352 (2012).
doi: 10.1371/journal.ppat.1002352 pubmed: 22241987 pmcid: 3252364
Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96. https://doi.org/10.1126/science.274.5284.94 (1996).
doi: 10.1126/science.274.5284.94 pubmed: 8810254
Price, D. A. et al. Avidity for antigen shapes clonal dominance in CD8
doi: 10.1084/jem.20051357 pubmed: 16287711 pmcid: 2212993
Martinuzzi, E. et al. acDCs enhance human antigen-specific T-cell responses. Blood 118, 2128–2137 (2011).
doi: 10.1182/blood-2010-12-326231
Nicoli, F. et al. Naive CD8
doi: 10.3389/fimmu.2018.02736 pubmed: 30619240 pmcid: 6308131
Gutjahr, A. et al. Cutting edge: A dual TLR2 and TLR7 ligand induces highly potent humoral and cell-mediated immune responses. J. Immunol. 198, 4205–4209. https://doi.org/10.4049/jimmunol.1602131 (2017).
doi: 10.4049/jimmunol.1602131 pubmed: 28432147

Auteurs

Laura Papagno (L)

Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, 75013, Paris, France.

Nozomi Kuse (N)

Center for AIDS Research, Kumamoto University, Kumamoto, 860-0811, Japan.

Anna Lissina (A)

Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, 75013, Paris, France.

Emma Gostick (E)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.

David A Price (DA)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.

Victor Appay (V)

Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, 75013, Paris, France. victor.appay@upmc.fr.
International Research Center of Medical Sciences, Kumamoto University, Kumamoto, 860-0811, Japan. victor.appay@upmc.fr.

Francesco Nicoli (F)

Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, 75013, Paris, France. nclfnc1@unife.it.
Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121, Ferrara, Italy. nclfnc1@unife.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Adjuvants immunologiques › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Cellules › Cellules cultivées › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytophotométrie › Cytométrie en flux › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Polynucléotides › Oligonucléotides › Oligodésoxyribonucléotides › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs de reconnaissance de motifs moléculaires › The TLR9 ligand CpG ODN 2006 is a poor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs de reconnaissance de motifs moléculaires › Récepteurs de type Toll › Récepteur-9 de type Toll-like › The TLR9 ligand CpG ODN 2006 is a poor...